PSORIATIC ARTHRITIS PATIENTS IN CLINICAL TRANSITION research hub

Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a randomized clinical trial.

This study looks at whether a new medicine, Guselkumab, can help people with early signs of psoriatic arthritis (PsA) before it fully develops. It compares Guselkumab with another medicine, Ciclosporin, to see which is better at preventing joint pain and inflammation.